Scarica l'app Stockscreener
12.79
51.36%
4.34
Dopo l'orario di chiusura:
12.03
-0.76
-5.94%
Precedente Chiudi:
$8.45
Aprire:
$8.29
Volume 24 ore:
1.39M
Relative Volume:
2.23
Capitalizzazione di mercato:
$21.37M
Reddito:
-
Utile/perdita netta:
$-13.52M
Rapporto P/E:
-17.28
EPS:
-0.74
Flusso di cassa netto:
$-10.03M
1 W Prestazione:
+122.05%
1M Prestazione:
+83.24%
6M Prestazione:
+257.26%
1 anno Prestazione:
-53.41%
Intervallo 1D:
$8.1122
$14.42
Intervallo di 1 settimana:
$7.09
$14.42
Portata 52W:
$2.86
$29.00
Kazia Therapeutics Limited Adr Stock (KZIA) Company Profile
Nome
Kazia Therapeutics Limited Adr
Settore
Industria
Telefono
01161298780088
Indirizzo
140 WICKS RD, NEW SOUTH WALES 2113, NSW
Confronta KZIA con altri titoli
| Azioni | Prezzo | Cap. di mercato | Reddito | Reddito netto | Flusso di cassa | EPS |
|---|---|---|---|---|---|---|
KZIA
Kazia Therapeutics Limited Adr
|
12.79 | 14.12M | 0 | -13.52M | -10.03M | -0.74 |
|
VRTX
Vertex Pharmaceuticals Inc
|
429.82 | 107.58B | 11.74B | 3.68B | 3.34B | 14.19 |
|
REGN
Regeneron Pharmaceuticals Inc
|
787.32 | 80.03B | 14.25B | 4.58B | 3.88B | 41.77 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
429.80 | 57.37B | 3.21B | 43.57M | 221.36M | 0.2405 |
|
ARGX
Argen X Se Adr
|
917.93 | 55.83B | 3.06B | 1.28B | 447.35M | 19.67 |
|
INSM
Insmed Inc
|
209.02 | 44.13B | 447.02M | -1.18B | -906.14M | -6.1812 |
Kazia Therapeutics Limited Adr Stock (KZIA) Upgrades & Downgrades
| Data | Azione | Analista | Modifica della valutazione |
|---|---|---|---|
| 2025-02-06 | Iniziato | Maxim Group | Buy |
| 2021-10-14 | Iniziato | Maxim Group | Buy |
| 2021-01-05 | Iniziato | H.C. Wainwright | Buy |
Kazia Therapeutics Limited Adr Borsa (KZIA) Ultime notizie
Kazia Therapeutics Limited (KZIA) Stock Price | Live Quotes & Charts | NASDAQ - StocksToTrade
Kazia Therapeutics reports immune complete response in TNBC - MSN
KZIA Shares Surge: Can This Momentum Last? - StocksToTrade
Kazia Therapeutics (KZIA) Stock Soars on Breakthrough Results in Breast Cancer Treatment - parameter.io
You might want to take a look at Kazia Therapeutics Limited ADR (KZIA) now - Setenews
Kazia Therapeutics receives Nasdaq delisting notice, plans to request hearing By Investing.com - Investing.com India
Kazia Therapeutics receives Nasdaq delisting notice, plans to request hearing - Investing.com
Kazia Therapeutics Achieves Initial iCR… - digitalmore.co
Kazia reports immune-complete response in metastatic breast cancer By Investing.com - Investing.com South Africa
Kazia reports immune-complete response in metastatic breast cancer - Investing.com
Kazia stock soars after patient shows complete response in TNBC trial - Investing.com Nigeria
[424B3] KAZIA THERAPEUTICS LTD Prospectus Filed Pursuant to Rule 424(b)(3) - Stock Titan
Kazia (Nasdaq: KZIA) reports iCR in metastatic TNBC and outlines Q4 oncology pipeline - Stock Titan
[6-K] KAZIA THERAPEUTICS LTD Current Report (Foreign Issuer) | KZIA SEC FilingForm 6-K - Stock Titan
[20-F] KAZIA THERAPEUTICS LTD Files Annual Report (Foreign Issuer) | KZIA SEC FilingForm 20-F - Stock Titan
How Does Wall Street Rate Shares Of DoubleDown Interactive Co Ltd ADR (DDI)? - fostersleader.com
Is Buying Stock In MediWound Ltd (MDWD) A Good Move Today? - fostersleader.com
Kazia Therapeutics stock seeks FDA guidance on paxalisib approval path - Investing.com
Kazia Therapeutics to Request FDA Type C Meeting to Discuss Overall Survival Data in GBM and Potential NDA Filing in Alignment with FDA initiative Project FrontRunner - Benzinga
Kazia (NASDAQ: KZIA) to request FDA Type C on GBM OS; NDA path under review - Stock Titan
Kazia (KZIA) secures PD-L1 degrader NDL2 with $1.39M payment - Stock Titan
Kazia Therapeutics Announces Collaboration and In-Licensing Agreement for First-in-Class PD-L1 Protein Degrader Program - Stock Titan
KZIA Stock Institutional Owners - Quiver Quantitative
Kazia reports 86% tumor reduction in expanded access case - Investing.com India
86% Tumor Reduction: Kazia's Experimental Cancer Drug Paxalisib Shows Dramatic Results in TNBC Patient Study - Stock Titan
Revolutionary AI Platform to Combat 25% of Childhood Brain Cancer Deaths: Kazia's New Research Initiative - Stock Titan
Kazia Therapeutics Supports Australian MRFF-Funded Project Developing AI-Driven Sequential Therapy Strategy for DIPG/DMG - Ariva
Kazia Therapeutics Achieves Breakthrough in Breast Cancer Treatment with Paxalisib - The Globe and Mail
Kazia Therapeutics Reports Complete Ex Vivo Disruption of Large Circulating Tumor Cell Clusters in Stage IV HER2-Positive Breast Cancer with Paxalisib Monotherapy - The Manila Times
100% Cancer Cell Cluster Elimination: Kazia's Breakthrough Drug Shows Perfect Score in Advanced Breast Cancer - Stock Titan
Leptomeningeal Metastases Market to Exhibit Growth at a - GlobeNewswire
Novogen Limited (NASDAQ:KZIA) Sees Large Growth in Short Interest - Defense World
Kazia Therapeutics Announces $2 Million Private Placement at Premium to Market - The Manila Times
Kazia Therapeutics raises US$2m via discounted private placement to fund trials | KZIA SEC FilingForm 6-K - Stock Titan
Kazia Therapeutics Announces At the Market Offering Agreement - The Globe and Mail
Kazia Therapeutics starts US$1.9M ATM ADS program; CEO exits board | KZIA SEC FilingForm 6-K - Stock Titan
Glioblastoma Market Forecast 2034: Clinical Trials, EMA, PDMA, FDA Approvals, Medication, Statistics, Revenue, Treatment, Therapies and Companies by DelveInsight - Barchart.com
Novogen (NASDAQ:KZIA) Raised to “Sell” at Wall Street Zen - ETF Daily News
Analysts Issue Forecasts for Novogen FY2025 Earnings - Defense World
Novogen (NASDAQ:KZIA) Upgraded by HC Wainwright to Strong-Buy Rating - Defense World
Novogen (NASDAQ:KZIA) Rating Increased to Strong-Buy at HC Wainwright - Defense World
Cancer Innovation Accelerates as Funding Cuts Loom and Biotechs Step Up - The Globe and Mail
Phase 1b Data Suggest Paxalisib Combo May Suppress CTCs in Metastatic TNBC - Targeted Oncology
Novogen (NASDAQ:KZIA) Shares Up 39.7% – Should You Buy? - Defense World
Ryde Group files US$100 M shelf; micro-cap float limits near-term raise | KZIA SEC FilingForm 424B3 - Stock Titan
Cancer Innovation Accelerates As Funding Cuts Loom And Biotechs Step Up - Barchart.com
Kazia Therapeutics stock soars after positive early cancer treatment data By Investing.com - Investing.com Nigeria
Kazia Therapeutics stock soars after positive early cancer treatment data - Investing.com Australia
Early Clinical Trial: New Drug Combo Slashes Breast Cancer Cells by 50% in Just 21 Days - Stock Titan
Kazia Therapeutics Reports Early Efficacy Data from First Triple-Negative Breast Cancer Patient Receiving Paxalisib Combination Regimen achieving >50% Reduction in Circulating Tumor Cells in Phase 1b Trial - Ariva
Short Interest in Novogen Limited (NASDAQ:KZIA) Declines By 28.0% - Defense World
Kazia Therapeutics Limited Adr Azioni (KZIA) Dati Finanziari
Reddito
Reddito netto
Flusso di cassa
EPS
0.53%
1.88%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):